neuroClues

neuroClues operates at the intersection of neurological diagnostics, medical devices, and digital biomarkers. Its core proposition is narrower than general-purpose eye-tracking vendors: the company combines a portable medical device, clinical protocols, automated biomarker computation, reporting, and secure cloud operations for healthcare and research settings. The platform records both eyes at up to 400 frames per second and is designed to operate without patient calibration, which may reduce examination friction compared with laboratory-based eye-tracking workflows. Its stated applications include Parkinson’s disease, Alzheimer’s disease, multiple sclerosis, and broader neurological assessment. The company’s CE-marked Class IIa status gives it a more clinically oriented positioning than consumer wearables or research-only tracking systems. No verified competitor set is included in the available company record, so market-share conclusions would be premature. The €10 million Series A in April 2026 and reported plans for European and US expansion indicate that neuroClues is moving from technology validation toward broader commercialization, while its relatively small employee range suggests it remains an early-stage specialist rather than an established diagnostics incumbent.

neuroClues has progressed from a 2020-founded neuroscience venture to a Series A medical-device company with a cumulative structured funding total of approximately $24.2 million. Its financing history shows four recorded rounds: a $4.9 million seed round announced on Nov 8, 2021, a $2.5 million European Innovation Council grant announced on Oct 5, 2022, a $5.3 million seed round announced on Apr 30, 2024, and an $11.5 million Series A announced on Apr 6, 2026. The Series A is the clearest inflection point, more than doubling the capital raised in the prior recorded equity rounds and supporting expansion across Europe and into the United States. Product development has also moved beyond a standalone sensor: neuroClues now describes an integrated portable device, clinical application, biomarker engine, automated reports, and secure cloud environment. Commercial scaling is reflected in the appointment of Bart Stulens as Chief Commercial Officer on Apr 8, 2026 and active hiring activity in France. The company remains relatively small, with an employee band of 11–50 and only two highlighted current positions, so execution capacity and evidence of recurring clinical adoption remain important open questions. No layoffs are reported.